menu
    • menu

    Company profile for MapLight Therapeutics

    NEW Drugs in Dev: 3
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS). By combining its set of proprietary technologies to identify and treat the defining symptoms of some of the most challenging central nervous system disorders, MapLight is introducing novel therapeutics that will bring hope and relief to countless patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MapLight TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Palo Alto, CA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://maplightrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/maplight-therapeutics-inc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Maplightrx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Maplight Therapeutics Shifts Phase 2 Study Results Timing To Q3
    Maplight Therapeutics Shifts Phase 2 Study Results Timing To Q3

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3215999/0/en/MapLight-Therapeutics-Updates-Expected-Timing-of-Topline-Results-for-Ongoing-Phase-2-Studies-to-Q3-2026.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    SandboxAQ & MapLight Announce Collaboration to Novel CNS Therapy
    SandboxAQ & MapLight Announce Collaboration to Novel CNS Therapy

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206094/0/en/SandboxAQ-and-MapLight-Therapeutics-Announce-Strategic-Collaboration-to-Discover-and-Develop-Novel-CNS-Therapies.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    MapLight Therapeutics Reports Q3 Results, Progress
    MapLight Therapeutics Reports Q3 Results, Progress

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199651/0/en/MapLight-Therapeutics-Reports-Third-Quarter-Financial-Results-and-Highlights-Corporate-Progress.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Maplight Therapeutics Completes IPO With Full Underwriters Option
    Maplight Therapeutics Completes IPO With Full Underwriters Option

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176533/0/en/MapLight-Therapeutics-Announces-Closing-of-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Maplight Goes Public Via $250M IPO To Fund Cobenfy Competitor
    Maplight Goes Public Via $250M IPO To Fund Cobenfy Competitor

    27 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/maplight-goes-public-250m-ipo-fund-cobenfy-competitor

    FIERCE BIOTECH
    27 Oct 2025
    Share Share
    Novo-Backed Maplight Valued At $787M In Nasdaq Debut
    Novo-Backed Maplight Valued At $787M In Nasdaq Debut

    27 Oct 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/maplight-therapeutics-valued-787-million-shares-jump-nasdaq-debut-2025-10-27/

    REUTERS
    27 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search